Rock Springs Capital Management’s Corvus Pharmaceuticals CRVS Stock Holding History

Rock Springs Capital Management’s Portfolio CRVS Stock Details CRVS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-150,000	Closed	-$816K	–	134
2019 Q4	$816K	Sell	150,000 -250,000	-63%	-$874K	0.03%	126
2019 Q3	$1.2M	Hold	400,000	–	–	0.05%	131
2019 Q2	$1.5M	Hold	400,000	–	–	0.05%	125
2019 Q1	$1.61M	Hold	400,000	–	–	0.06%	123
2018 Q4	$1.47M	Sell	400,000 -175,000	-30%	-$1.19M	0.07%	127
2018 Q3	$4.93M	Hold	575,000	–	–	0.18%	118
2018 Q2	$6.31M	Hold	575,000	–	–	0.24%	110
2018 Q1	$6.63M	Buy	575,000 +152,400	+36%	+$1.44M	0.28%	98
2017 Q4	$4.38M	Hold	422,600	–	–	0.2%	110
2017 Q3	$6.74M	Hold	422,600	–	–	0.31%	93
2017 Q2	$5.11M	Hold	422,600	–	–	0.26%	98
2017 Q1	$8.78M	Sell	422,600 -27,400	-6%	-$429K	0.51%	64
2016 Q4	$6.43M	Hold	450,000	–	–	0.43%	68
2016 Q3	$7.4M	Hold	450,000	–	–	0.46%	62
2016 Q2	$6.42M	Sell	450,000 -6,887	-2%	-$93K	0.48%	65
2016 Q1	$6.63M	Buy	+456,887	New	+$6.56M	0.56%	59

Other funds holding CRVS

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

ASP

Adams Street Partners Chicago, Illinois $260M AUM 30.38% 1-Year Est. Return

NHAS

Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

CHI Advisors New York $252M AUM 56.99% 1-Year Est. Return

Rock Springs Capital Management's CRVS Position: Q1 2020 in Review

Rock Springs Capital Management sold out of Corvus Pharmaceuticals (CRVS) in Q1 2020, closing a stake of 150,000 shares — an estimated $816K sold.

Rock Springs Capital Management first reported a position in CRVS in Q1 2016 and held it in 16 quarters. The position peaked at $8.78M in Q1 2017. 43 funds tracked by Wall St. Rank hold CRVS as of Q1 2020.

Rock Springs Capital Management reported no remaining Corvus Pharmaceuticals position as of Q1 2020 after selling out during the quarter.
Rock Springs Capital Management sold 150,000 Corvus Pharmaceuticals shares in Q1 2020, an estimated $816K.
Rock Springs Capital Management first reported a position in Corvus Pharmaceuticals in Q1 2016 and held it in 16 quarters.
Rock Springs Capital Management's Corvus Pharmaceuticals position peaked at $8.78M in Q1 2017.
43 funds tracked by Wall St. Rank held Corvus Pharmaceuticals as of Q1 2020.

Based on Rock Springs Capital Management's 13F filing for Q1 2020, filed 15 May 2020.